RDAF position on the KVV / KLV revision

21 Nov, 2023

The revision of the Health Insurance Ordinance (KVV/OAMal) and the Health Benefits Ordinance (KLV/OPAS), presented by the Federal Council in September, will further deteriorate access to treatment and quality of care for rare disease patients in Switzerland. The specific needs of patients with rare diseases are still not fully reflected in the KVV and KLV.

The RDAF supports the improvements made to the system for reimbursement in individual cases, including the involvement of therapeutic experts in the benefit assessment, the obligation for insurers to justify negative decisions and the possibility to conduct joint assessments. However, the RDAF is of the opinion that the tool to be used by all insurers as of January 2024, the OLUtool, is not adapted to the specific characteristics of rare diseases and orphan drugs. Additionally, mandatory price cuts could delay access to treatment for patients with rare diseases, who are often facing a lack of therapeutic alternatives.

Read the RDAF full statement here.

Internationaler Tag der Seltenen Krankheiten 2026: Gemeinsam Fortschritte stärken und die Versorgung nachhaltig verbessern

Am heutigen Internationalen Tag der Seltenen Krankheiten erinnert das Rare Disease Action Forum (RDAF) daran, dass über 500'000 Menschen in der Schweiz von einer seltenen Erkrankung betroffen sind, viele von ihnen weiterhin ohne gesicherten Zugang zu Diagnose,...

Gemeinsam für eine bessere Versorgung

Am 28. Februar 2025 begehen wir den Internationalen Tag der Seltenen Krankheiten. Dieser Tag macht darauf aufmerksam, dass Millionen von Menschen weltweit – und auch hier in der Schweiz – mit seltenen Krankheiten leben und oft vor grossen Herausforderungen stehen. Das...